(Q37682594)

22 August 2017

1 reference

title

Metabolites in safety testing: "MIST" for the clinical pharmacologist (English)

1 reference

22 August 2017

C B Frederick

1

1 reference

22 August 2017

R S Obach

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

27 January 2010

1 reference

Clinical Pharmacology & Therapeutics

22 August 2017

published in

1 reference

22 August 2017

volume

87

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

345-350

1 reference

Drug metabolites in safety testing

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Interpretation and considerations on the safety evaluation of human drug metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Acyl glucuronide reactivity in perspective: biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Acyl glucuronide drug metabolites: toxicological and analytical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Applying mechanisms of chemical toxicity to predict drug safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

A comprehensive listing of bioactivation pathways of organic functional groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Predicting circulating human metabolites: how good are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

A holistic strategy for characterizing the safety of metabolites through drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

Drug metabolites in safety testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

7 January 2021

Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

7 January 2021

Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

7 January 2021

Metabolites and safety: What are the concerns, and how should we address them?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

7 January 2021

MSE with mass defect filtering for in vitro and in vivo metabolite identification

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

7 January 2021

LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

7 January 2021

A regulatory perspective on issues and approaches in characterizing human metabolites

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.283

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.283

1 reference

22 August 2017

1 reference